Trial Profile
Safety and Efficacy of an Immune Response Modifier to Treat Inoperable Advanced Melanoma Skin Lesions
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 May 2018
Price :
$35
*
At a glance
- Drugs 852A (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Pfizer
- 17 May 2018 New trial record